home > drugs a-z list > trilisate (choline magnesium trisalicylate) drug center > trilisate (choline magnesium trisalicylate) drug - clinical pharmacology

TRILISATE (choline magnesium trisalicylate) Tablets/ Liquid contain salicylate with anti- inflammatory, analgesic and antipyretic action. On ingestion of TRILISATE (choline magnesium trisalicylate) Tablets/ Liquid, the salicylate moiety is absorbed rapidly and reaches peak blood levels within an average of one to two hours after single doses of the tablets or liquid. The primary route of excretion is renal; the excretion products are chiefly the glycine and glucuronide conjugates. At higher serum salicylate concentrations, the glycine conjugation pathway becomes rapidly saturated. Thus, the slower glucuronide conjugation pathway becomes the rate limiting step for salicylate excretion. In addition, salicylate excreted in the bile as glucuronide conjugate may be reabsorbed. These factors account for the prolongation of salicylate half-life and the nonlinear increase in plasma salicylate level as the salicylate dose is increased. The serum concentration of salicylate is increased by conditions that decrease glomerular filtration rate or proximal tubular secretion.

The bioequivalence of TRILISATE (choline magnesium trisalicylate) Liquid and Tablets 500 mg/ 750 mg/ 1000 mg has been established. With the tablets, a steady- state condition is usually reached after 4 to 5 doses, and the half- life of elimination, on repeated administration of tablets, is 9 to 17 hours. This permits a maintenance dosage schedule of once or twice daily. Unlike aspirin and certain other non-steroidal anti-inflammatory agents, such as arylpropionic acid derivatives and arylacetic acid derivatives, choline magnesium trisalicylate, at therapeutic dosage levels, does not affect platelet aggregation, as shown by in vitro and in vivo studies.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.